Is Aridis Pharmaceuticals, Inc. (ARDS) a Buy, Sell, or Hold?
OTC : ARDS
Aridis Pharmaceuticals, Inc. — News
$0.0001 USD
$0 (0.0%)
- Volume
- 40.1K
- Average Volume
- 15.13K
- Market Capitalization
- $4.46K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.05
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.32
| Source | Headline |
|---|---|
|
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited
RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where gurufocus.com - 2026-05-31 09:00:00 |
|
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
RYBREVANTÂ (amivantamab-vmjw) plus LAZCLUZEÂ (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR gurufocus.com - 2026-05-29 15:00:00 |
